
Novartis commits $23bn to US manufacturing amid tariff threats
Novartis will invest $23bn in US-based manufacturing and research and development (R&D) over the next five years, becoming the latest pharmaceutical company to shift operations to the US in response to potential tariffs. The Swiss drugmaker said it …